{"id":1714,"date":"2025-06-16T08:27:56","date_gmt":"2025-06-16T13:27:56","guid":{"rendered":"https:\/\/www.rqmplus.com\/?p=1714"},"modified":"2025-07-09T05:46:51","modified_gmt":"2025-07-09T10:46:51","slug":"what-is-the-benefit-of-seeing-the-brain","status":"publish","type":"post","link":"https:\/\/www.rqmplus.com\/blog\/what-is-the-benefit-of-seeing-the-brain\/","title":{"rendered":"What is the Benefit of Seeing the Brain?"},"content":{"rendered":"\n

Defining and demonstrating clinical benefits of diagnostic imaging<\/h2>\n\n\n\n

The prevalence of research into brain imaging modalities has solidified this practice into a relied-upon tool to provide information on a variety of neurological conditions. These devices are tools to not only see the structure of that once elusive yet fascinating part of the anatomy but to also guide treatments for nearly any neurological condition including epilepsy, stroke, cancer, and Parkinson\u2019s disease to name a few.<\/p>\n\n\n\n

When it comes to assessing these imaging devices and determining regulatory and market acceptability<\/a>, the fundamental question is \u201cdo the benefits outweigh the risks?\u201d This question is captured in both GSPRs 1 and 8 (state GSPRs) and rely on the clinical evaluation report (CER) to demonstrate compliance.<\/p>\n\n\n\n

Intuitively, the answer is straightforward. Yes, of course we want a noninvasive method to see the brain. These pictures give us valuable insight into lesions, masses, and other structural anomalies under the surface. However, if you\u2019ve ever submitted a CER to a notified body, you know that intuitive arguments don\u2019t take you very far. We need to dig into the data, figure out a way to define benefits and risks, and provide evidence to justify the acceptability of the device.<\/p>\n\n\n\n

Balancing Benefits and Risks in Medical Imaging Devices<\/h2>\n\n\n\n

Risk is generally the easier part to define, which is done by considering any potential harms to the patient. The most prevalent modern imaging techniques include MRI, CT- and PET-scans. While these methods are noninvasive, that doesn\u2019t always equate to no risk. For example, some of these technologies emit radiation to both patient and user if precautions are not taken. Downstream cumulative effects of exposure can lead to very serious health risks, but are they acceptable considering the benefits of the technology?<\/p>\n\n\n\n

Describing benefits of the device should be done with the perspective of the state of the art in medicine. What are the alternatives to the device under evaluation? If this device was not on the market, what other options do clinicians have to view the brain? Consider a glioma patient whose healthcare provider uses diffusion tensor imaging (DTI) to determine tumor grade. Without DTI, the clinician\u2019s other options may be a standard MRI or CT-scan.<\/p>\n\n\n\n

Communicating Value for Regulatory and Market Success<\/h2>\n\n\n\n

Since the device does not provide a direct therapeutic effect, this is where manufacturers get stuck. They find it difficult to put a finger on the benefits of a diagnostic imaging device. Clinical benefit, by definition, is the positive impact of a device on the health of an individual, expressed in terms of any of the following:<\/p>\n\n\n\n